propafenone has been researched along with Dyspnea in 3 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Dyspnea: Difficult or labored breathing.
Excerpt | Relevance | Reference |
---|---|---|
"The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 9.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
"The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)." | 5.10 | Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duricova, J | 1 |
Perinova, I | 1 |
Jurckova, N | 1 |
Kacirova, I | 1 |
Grundmann, M | 1 |
Lip, GY | 1 |
Fauchier, L | 1 |
Freedman, SB | 1 |
Van Gelder, I | 1 |
Natale, A | 1 |
Gianni, C | 1 |
Nattel, S | 1 |
Potpara, T | 1 |
Rienstra, M | 1 |
Tse, HF | 1 |
Lane, DA | 1 |
Pritchett, EL | 1 |
Page, RL | 1 |
Carlson, M | 1 |
Undesser, K | 1 |
Fava, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for propafenone and Dyspnea
Article | Year |
---|---|
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
1 trial available for propafenone and Dyspnea
Article | Year |
---|---|
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2003 |
1 other study available for propafenone and Dyspnea
Article | Year |
---|---|
Clinically important interaction between metoprolol and propafenone.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Cytochrome P-450 CYP2D6; | 2013 |